HEHEUMATIC FEVER continues to exact a fearsome toll in cardiovascular morbidity and mortality in the economically developing areas of our planet, including the Middle East, the Indian subcontinent, and many nations of South America and Africa. It has been estimated, for example, that rheumatic heart disease causes 25 percent to 40 percent of all cardiovascular disease in the third world. 1.2 The situation in North America and western Europe, however, stands in striking contrast to that in the developing countries. In the West, the incidence of acute rheumatic fever (ARF) has declined steadily over the course of the 20th century. The disease now occurs primarily in the most crowded and povertystricken of our urban ghettos. The rarity of ARF in economically privileged populations is illustrated by the report in this issue of Clinical Pediatrics from Fairfax County, Virginia. Dr. Richard Schwartz and his colleagues found that, by 1980, the annual ARF attack rate among persons less than 20 in this upper-class suburban county had fallen to fl.~ per 100,000 population. To be sure, the Fairfax County incidence data may be criticized on several counts. For example, we aren't told whether attempts were made to survey hospitals other than Fairfax Hospital, nor does it appear that efforts were mounted to identify nonhospitalized cases. Nevertheless, even allowing for an error twofold or greater in magnitude, the rate reported is extraordinarily low. Moreover, similarly low rates have been ascertained recently in Memphis, Tennessee,3 and Baltimore, Maryland.4 Data such as these raise two critical questions. Why is ARF disappearing from the affluent neighborhoods of suburban America, and what are the implications of this trend in regard to management of streptococcal pharyngitis ?
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Although the explanation for the dramatic decline in ARF incidence remains controversial, it is likely multi-factorial. Crowding is known to facilitate the person-to-person transmission of group A streptococci. To the extent that upward socioeconomic mobility results in less crowded bedrooms and classrooms, it may contribute to the decrease in ARF incidence. Although the decline in the disease began prior to the antibiotic era, antibiotic therapy of &dquo;strep throat&dquo; undoubtedly has played a role in the continued diminution in ARF rates over the past four decades. Moreover, secondary prophylaxis has clearly been critical in presenting the devastating cardiac sequelae of recurrent ARF. On the other hand, changes in host susceptibility to development of ARF following streptococcal upper respiratory infection seem unlikely, because the incidence of the disease has plummeted over such relatively few human generations.
In this writer's opinion, one major factor contributing to the decline of ARF is a change in the rheu-matogenic potential of currently prevalent group A streptococci. The evidences for this phenomenon are too extensive to enunciate fully here, but they may be summarized briefly. (a) In the days when ARF was prevalent in the US, there were marked geographic variations in the incidence of the disease that are most easily explained by variations in the rheumatogenicity of locally prevalent streptococcal strains. (b) In the preantibiotic era, there were very well documented outbreaks of severe streptococcal pharyngitis that failed to initiate ARF or even to elicit recurrences in rheumatic hosts.' (c) Analysis of specific streptococcal serotypes known to be associated with discrete outbreaks of ARF6 reveals that certain types, such as type 5, are markedly over-represented when compared to their general prevalence. Likewise, other types, particularly type 12, are notably under-represented. (d) Prospective studies conducted in Memphis, Tennessee, 7,8 south Trinidad,' and Santiago, Chile, 10 provide evidence for contrasts in the epidemiology of ARF and poststreptococcal glomerulonephritis, when both occur in the same population, and indicate that the strains causing each sequel are likely distinct.
As regards the second of the questions set forth above, namely, the implications of declining ARF incidence for management of &dquo;strep throat,&dquo; there is even greater controversy. Most such controversy rages over the role of the throat culture. One camp feels the test is effete. They point out that it is often overpriced and, at any rate, is unable to differentiate truly infected patients from streptococcal carriers. Moreover, the test is often misused by physicians, who tend to initiate therapy prior to learning the results of the throat culture and often fail to discontinue antibiotics even when the test is negative.
Although the above arguments opposed to widespread use of the throat culture have some merit, this writer subscribes to a different view. It seems to me that, as ARF becomes a rarity in the populations served by privately practicing pediatricians, there is even less justification for management strategies that needlessly expose the great majority of school-aged sore throat pat~ents {~.e., those without &dquo;strep throat&dquo; or local suppurative complications such as otitis or sinusitis) to prolonged courses of antimicrobial therapy. Although the positive predictive value of the throat culture is only about 50 percent under ordinary circumstances, the negative predictive value may be estimated to be in the 98 percent range. I know of no alternative strategy that so effectively rules out &dquo;strep throat&dquo; and at the same time provides assurance that the rare patient at risk for ARF (as were the 23 subjects in Fairfax County who developed the disease between 1970 and 1980) will be adequately protected. All this is not to say that our current strategies are optimal. There is clearly a need for more widely available resources to process streptococcal screening throat cultures rapidly and inexpensively. The emphasis placed by the American Heart Association (AHA) on intramuscular benzathine penicillin G&dquo; is open to question now that the risk of ARF is so low. The ground rules for culture of family contacts require further assessment. Improved methods of laboratory diagnosis must be investigated. One such approach would detect group A streptococcal antigen directly in pharyngeal secretions by immunologic means, thus obviating the need for throat cultures entirely.12.13 Finally, we need from the basic research laboratories the tools with which to identify those streptococci with strong rheumatogenic potential and those sore throat patients who may be constutitionally predisposed to the development of ARF. 14 Recently, the Committee on Rheumatic Fever and Bacterial Endocarditis of the AHA convened a select panel to discuss &dquo;Management of Streptococcal Pharyngitis in an Era of Declining Incidence of Acute Rheumatic Fever.&dquo; The proceedings of that conference, which will be published,'S represent a first step in facing many of the issues raised by the continued prevalence of streptococcal pharyngitis and the (thankfully) ever-diminishing incidence of ARF in the developed countries of the world. For the foreseeable future, we as physicians will have to deal with the awkward situation, exemplified by the Fairfax County experience, of having too little rheumatic fever to justify heroic community-wide control measures but too much rheumatic fever to ignore completely. Steering an appropriate middle course will be a challenge to our sense of perspective, clinical judgment, and plain common sense.
